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ABSTRACT
Objective: Blood pressure (BP) pursues circadian rhythms projecting its highest values during early morning and lowest during night. The aim of the 
present investigation was to design a newer programmable chronotherapy based capsule system containing delayed release microspheres of losartan 
potassium for effective management of hypertension.
Methods: First, the microspheres were prepared with Eudragit RS100 by optimization technique through the application of Design Expert® software. 
The optimized microsphere formulation was filled in a capsule shell, and these shells were coated with 10% w/v Eudragit L100:Eudragit S100 
(in ratio 1:2), in isopropyl alcohol: water as solvent system, to provide the necessary delay in emptying of capsule content. The whole capsular system 
was evaluated by various characteristic formulation parameters. Validation of optimization model and statistical interpretation of results was done 
using analysis of variance.
Results: The results indicated that the optimized triple coated capsule shells showed an extended release of drug from microspheres after a lag time 
of 4 h.
Conclusion: Conclusively, the chronotherapeutic system of losartan potassium was successfully developed to be dosed at bedtime that could benefit 
from the known circadian rhythms of the disease to control the BP for once a day therapy.
Keywords: Statistical design approach, Eudragit, Chronotherapy, Coated capsule system, Losartan potassium.
INTRODUCTION
In the body, many physiological functions are regulated by transient 
release of bioactive principles at a specific time. Hence, to mimic the 
functions of living organisms, advances in research are aiming toward 
synchronizing the drug delivery in a manner consistent with the 
body’s circadian rhythms to bring both commercial and therapeutic 
value to health care. The last decade has witnessed the emergence of 
chronotherapeutic drug delivery system for several diseases. Large 
data-based analysis and epidemiological studies have demonstrated 
that many cardiovascular events such as myocardial infarction, stroke, 
and sudden cardiac death cluster during early morning at around 6 am 
and then at 12 noon. It has been attributed to the fact that there are 
marked circadian rhythms in blood pressure (BP) that accounts for a 
sharp rise in BP during early morning and then in the afternoon; after 
that, BP declines during night time falling 15–20 mm Hg between 
8:00 pm and 2:00 am. This rise in BP is mainly ascribed to enhanced 
plasma-renin activity [1-3]. Thus, one of the newest advances in 
antihypertensive therapy is the design of drugs according to the 
chronotherapy that would deliver the drug in highest concentrations at 
the time of maximum need (in early morning hours) after an initial lag 
phase characterized by a period of no drug release.
Thus, the aim of the present investigation is to design a delayed release 
multiparticulate chronotherapeutic capsular drug delivery system 
containing losartan potassium microspheres. Losartan potassium is an 
angiotensin receptor blocker that works by antagonizing the rennin-
angiotensin-aldosterone system; later being one of the contributing 
factors for the marked rise in early morning BP. Hence, an attempt has 
been made to develop a newer dosage form of losartan potassium to be 
dosed at bedtime and release the drug after a lag time of 2 h. Moreover, 
losartan potassium tends to remain lesser solubilized in simulated 
gastric fluid (SGF) pH 1.2 that accounts for its low absorption while 
its solubility increases in SIF pH6.8. The drug would be released in SIF 
pH 6.8 in a controlled manner; thereby, plasma drug levels would rise 
during the early morning when BP is at its highest (as administration 
of dosage form is not feasible so early); thus, preventing the major 
cardiovascular events [4-7]. Hence, the system could benefit from the 
known circadian rhythms of the disease to control the BP for once a day 
therapy and overcome shortcomings of the currently available typical 
conventional and controlled release formulations.
The microspheres of losartan potassium were prepared using 
polymethacrylate polymer, Eudragit RS100, by emulsion solvent 
evaporation method through the application of statistical design 
approach. Eudragit RS100 is being increasingly employed for the 
development of oral sustained release microspheres [8,9]. It is a low 
permeability neutral polymer that is insoluble in water and digestive 
juices but swells due to the presence of quaternary ammonium groups; 
thus, releases the drug by diffusion [10]. The optimized microsphere 
formulation was filled into hard gelatin capsule shells. To synchronize 
the drug release with the circadian rhythms for hypertension, the shell 
was coated with Eudragit L100 [11] to obtain the desired lag time based 
on preliminary trials conducted to optimize the ratio.
MATERIALS AND METHODS
Materials
Losartan potassium was obtained as a gift sample from Theon 
Pharmaceuticals Pvt., Ltd., Baddi. Eudragit RS 100, L100 was procured 
from Theon Pharmaceuticals Pvt., Ltd., Baddi. Isopropyl alcohol, Light 
liquid paraffin, n-hexane, methanol, and dichloromethane were obtained 
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from Loba Chemicals Pvt., Ltd. PEG 6000, Talc, Span 80, potassium 
dihydrogen orthophosphate, sodium hydroxide, and concentrated 
hydrochloric acid were purchased from S. D. Fine Chemicals.
Methods
Preparation of microspheres: Statistical design approach
Statistical experimental designs are powerful and systematic tools in 
multiple factor optimizations in fewer experimental trials. Hence, for 
preparation of microspheres, response surface methodology employing 
central composite design (CCD) was applied. The microspheres of 
Losartan potassium were prepared by varying the drug: polymer ratio 
and codissolving them at room temperature into a mixture methanol-
acetone (1:1 v/v) with continuous stirring using Remi’s mechanical 
stirrer (model: RQ - 121/D). The drug: polymer ratio and stirring speed 
were varied as per the CCD experimental design as shown in Table 1. 
The resultant dispersion was slowly introduced into light liquid paraffin 
containing span 80 (1% w/w) as an emulsifying agent. Light liquid 
paraffin was then decanted, and the microspheres were separated by 
filtration followed by washings with n-hexane to remove paraffin. The 
resulting microspheres were dried at room temperature for 24 h and 
evaluated for various in vitro parameters [12-14].
Optimization and validation model
To optimize the formulation variables, factors selected for study were 
drug: polymer ratio (A) and stirring speed (B) taken at five different 
levels, namely – alpha, low, center point, high level, and +alpha level. 
Diverse batches of losartan potassium loaded Eudragit microparticles 
were prepared as per the CCD, and a total of 13 runs were presented 
by the Design Expert® software [15-18]. The response or dependent 
variables studied were mean particle size (Y1), drug entrapment 
efficiency (Y2), percent yield (Y3), and drug release at 8th h (Y4). The 
design matrix along with the investigated response variables is shown 
in Table 1. Experimental findings were analyzed using analysis of 
variance (ANOVA) by fitting the response figures in the run design.
The response (Yi) in each testing run was calculated by carrying out a 
regression analysis to develop equations for dependent variables (Y1-Y4).
Yi = β0 + β1A+ β2B+β3AB+β4A2+ β5B2 Eq. (A.1)
Where, Y is estimated response of dependent variables,
β0 is the intercept of the polynomial equation,
β1-5 represents estimated regression coefficient for factor A and B
AB are the coefficients corresponding interaction and
A2 and B2 represent the quadratic effects.
ANOVA was also used to obtain the F-values, p-values, and multiple 
correlation coefficients (R2); adjusted and predicted R2, lack of fit and 
PRESS value for authenticating the suitability of models. Exhaustive 
matrix seeks over the experimental domain was performed to find 
out the solutions and then checkpoint formulations were selected to 
assess the optimization capability of the model generated through 
CCD [19,20]. The experimentally obtained results were then compared 
with the predicted responses obtained from the equations of the model 
and residuals were calculated.
Evaluation of microparticles
Microparticles were evaluated for micromeritic properties by measuring 
the angle of repose, bulk density, tapped density, Carr’s index, and 
Hausner ratio using standard reported procedures [21]. The average 
particle size of microspheres was analyzed by simple optical microscopy 
method using the ocular lens and stage micrometer. Approximately 
300 microspheres were counted and the average equivalent spherical 
diameter was measured [22-25]. The drug entrapment efficiency was 
determined by taking accurately weighed microspheres equivalent to 
25 mg of losartan potassium and crushed to obtain a fine powder. The 
powder was dissolved in 100 ml of phosphate buffer pH 6.8 in a conical 
flask. The solution obtained was filtered, suitably diluted and analyzed 
spectrophotometrically using ultraviolet-visible (UV-VIS) double beam 
spectrophotometer at 235 nm. All the readings were taken in triplicate. 
Drug content was determined by the following formula:
Drug Entrapment Efficiency %




Amount of Drug initiallyTaken
×100
 Eq. (A.2)
The microspheres obtained were weighed accurately, and the 
percentage yield was calculated as the weight of losartan potassium 







×100  Eq. (A.3)
Table 1: Central composite design matrix, the observed responses, and actual or coded values
Runs Independent variables Dependent variables






Drug release at 8th h 
(Y4), %
1. 1 −1 169.2±1.23 71.37±1.23 65.49±0.74 67.96±2.62
2. 0 0 121.26±2.38 79.73±1.09 76.49±1.73 76.55±1.29
3. −1 1 102.28±2.03 70.39±1.54 75.15±2.47 75.94±0.47
4. 1 1 140.66±0.86 74.18±1.25 74.59±1.74 74.69±1.20
5. 0 0 120.48±1.01 78.44±0.89 76.68±1.26 75.35±1.40
6. −1 −1 119.69±1.03 69.3±2.26 77.98±1.74 76.68±0.82
7. 0 −1.41421 145.69±0.36 73.05±0.63 70.26±1.23 64.19±2.95
8. −1.41421 0 100.96±1.47 67.95±1.78 76.85±2.05 77.19±2.40
9. 1.41421 0 163.79±1.59 73.67±1.78 67.95±0.86 73.89±1.23
10. 0 0 120.03±1.15 79.1±0.83 67.45±0.55 80.64±2.29
11. 0 0 119.49±1.33 80.74±1.02 69.64±1.32 66.55±3.54
12. 0 0 120.55±0.38 78.88±1.90 65.29±1.96 80.95±2.78
13. 0 1.41421 113.68±2.59 75.96±2.44 62.56±1.08 79.25±1.40
S. 
No.
Independent variables Coded and actual levels
(−1.41421) alpha level −1 (low) 0 (middle) 1 (high) (+1.41421) alpha level
1. Drug: polymer ratio (w/w), A 1.58 1:2 1:3 1:4 4.41
2. Stirring speed (rpm), B 717 800 1000 1200 1282
±S.D. (n=6). SD: Standard deviation
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On the basis of the optimization and validation model, the optimized 
formulation was selected for further analysis. Fourier-transform 
infrared (FTIR) spectra of pure drug and optimized formulation were 
recorded using attenuated total reflection-FTIR spectrophotometer to 
investigate any possible interaction between drug-loaded microspheres. 
The morphology of optimized formulation of microspheres was 
examined by scanning electron microscope (SEM) analysis using 
SEM; Jeol JSM-6400, Japan. To analyze the existence condition of LP 
in the microspheres, digital signature certificate (DSC) of the LP, LP 
microspheres were carried out.
In vitro drug release study was carried out in simulated physiological 
pH 6.8 using USP Type I dissolution apparatus at 37±0.5°C to calculate 
the amount of drug released from microspheres. The assembly was 
operated at 100 rpm under sink conditions thereby maintaining the 
constant dissolution volume of 900 ml. The sample was withdrawn 
at suitable time intervals and replaced with fresh equal volume of 
dissolution medium. The samples withdrawn were analyzed using double 
beam UV-VIS spectrophotometer at 235 nm to determine the percent 
drug released. The dissolution data so obtained were fitted to various 
drug-release kinetic models such as zero-order, first-order, Higuchi, 
and Korsmeyer-Peppas model. The release kinetics was assessed by 
comparing the values of the regression coefficient (r2) [28,29].
Filling of capsule shell with optimized microparticle formulation
After optimization of coating, the uncoated capsule bodies were taken 
and filled with optimized microsphere formulation equivalent to 25 mg 
of losartan potassium. The capsule was sealed by fixing the cap of shell 
over capsule body.
Coating of filled capsule shell
The whole capsule system containing optimized microparticle 
formulation was optimally coated with plasticized 10% w/v Eudragit 
L100 in isopropyl alcohol: water plasticized with 10% PEG 6000 
containing talc as a glidant. The coating was done by dip coating 
method, and the number of coatings was varied from 1 to 4 to attain 
8–10% weight gain [11,30-33]. The design scheme for the development 
of capsule-based chronotherapeutic system has been shown in Fig. 1.
Evaluation of coated capsule shells containing optimized 
formulation
Ten capsules were selected randomly; thickness of uncoated and coated 
capsules was measured using digital screw gauge. Coating thickness 
was determined by measuring the difference between thicknesses 
before and after coating. The time taken by the coating to dissolve as 
indicated by the bursting of capsule shell was reported as lag time and 
evaluated using dissolution test apparatus for first 2 h in SGF pH 1.2 
and SIF pH 6.8 for remaining time. A dissolution study was carried 
out using USP type I apparatus. Coated capsules were immersed in 
900 ml of SGF pH 1.2 maintained at 37±0.5°C. Dissolution was carried 
out for 2 h at 100 rpm and then shifted to pH 6.8 medium by adding 
concentrated high pH media in the same vessel. This pH shift simulated 
the transition from stomach to intestines for remaining dissolution 
testing until 10 h [34]. Aliquots of 5 ml were withdrawn at suitable time 
intervals from the dissolution assembly and replaced with an equal 
amount of fresh buffer. The samples taken were analyzed at 235 nm 
spectrophotometrically and percent drug released was calculated.
RESULTS
Formulation optimization of microparticles of losartan potassium
For the preparation of microcapsules, emulsion solvent evaporation 
was employed using a mixed solvent system (methanol-acetone) as the 
dispersed phase and light liquid paraffin as an immiscible continuous 
phase stabilized with span 80 as an emulsifier. Judicial selection of 
solvent system was done based on their dielectric constants. The 
solvents having dielectric constant above 10 and below 40 reflect poor 
miscibility in light liquid paraffin; therefore, paraffin was preferred as 
a continuous phase in which both losartan potassium and Eudragit 
RS100 are scantily soluble [35]. 13 formulations were designed by 
applying CCD to optimize the composition and process variables.
Statistical data analysis and model validation
Models for different responses were generated by means of Design 
Expert® software. The calculated values of the response variables are 
shown in Table 1. Linear, quadratic, cubic, and cross-product (2FI) 
models were generated by the software for the responses, and the fit 
summary has been represented in Table 2.
The equations generated (Table 3) were used to quantify the response 
data and carried factors along with the coefficients. Positive sign of 
coefficient indicated synergistic effect (increase in response) while 
the negative sign indicated antagonistic effect (decrease in response 
values) as the factor was changed from low to high level [36]. The 
values of coefficients of linear equations indicated that the formulation 
variables had a controlling effect on the microsphere properties.
The ANOVA for the regression model demonstrated that the quadratic 
model was greatly significant as indicated by p<0.0001 and R2 value as 
shown in Table 4.
Mean particle size
The values for mean particle size showed a broad variation ranging 
from 100.96±1.47 to 169.20±1.23 µm. The data, as well as model, 
signified that the` independent variables drug: polymer ratio (A) 
and stirring speed (B), their interaction term (AB) and the quadratic 
terms (A2 and B2) showed a significant effect on particle size (Y1), 
p<0.0001. Expanding the drug: polymer proportion brought about the 
mean microparticle size to move toward higher value, as indicated by 
the positive coefficients of A. On the other hand, mean particle size 
decreased with increase in stirring speed as indicated by the negative 
coefficients of B, p<0.0001. It was observed that size decreased with 
increase in stirring speed and time up to a certain mid-level and then 
onward it remained constant or higher.
Entrapment efficiency
The values of drug entrapment efficiency (Y2) for the various 
experimental runs ranged between 67.95±1.78 and 80.74±1.02%. The 
Fig. 1: Stages in the development of capsule-based chronotherapeutic system
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model showed that drug: polymer ratio (A) and stirring speed (B) had a 
positive effect on entrapment efficiency, (p<0.0001). With the increase 
in independent variables, the entrapment efficiency increased to the 
middle level than it started decreasing on further increase in A and B.
Percent yield
The yield values for all the runs demonstrated wide difference going 
from a lowest of 62.56±1.08 to highest of 77.98±1.74%. The data 
indicated that percent yield was strongly dependent on the independent 
variable.
In vitro drug release
In vitro drug release data for all the experimental runs ranged between 
64.19±2.62 and 80.95±2.78%.
Validation by checkpoint formulation (CPF) and optimization
To approve the model equations resulting from regression analysis, 
four CPFs were selected randomly as recommended by the listing of 
solutions and CPFs were formulated. Table 5 shows the predicted and 
experimental values of both the responses and the value of residuals 
obtained.
Numerical optimization method was applied to arrive at the optimized 
formulation through the desirability function approach. With the 
view of keeping in mind to use the smallest size of dosage form, so as 
to incorporate in the capsule shell, the desirable levels of responses 
were constrained to mean particle size “in range,” “maximum” percent 
yield and entrapment efficiency, and drug release at 8th h up to 80%. 
On analyzing the various dependent variables and far-reaching 
assessment of practicality of exhaustive matrix seek, the accompanying 
blend of independent variables was recommended by the software with 
desirability function of 0.840. The desirability plot for the optimized 
losartan potassium microparticles (OLMP) formulation has been 
shown in Fig. 2.
Batches of losartan potassium microspheres (OLPM) were developed 
using these optimum process variable settings and evaluated for 
responses. The results obtained for response variables were mean 
particle size of 112.41±1.27, entrapment efficiency of 78.67± 1.62%, 
percent yield of 76.27%, and drug rel at 8th h around 77.61±1.05% with 
an error value <1. To graphically envision the effect of formulation/
operation variables on the output variables, contour and response 
surface plot were constructed using the software as shown in Fig. 3.
Formulations of microspheres indicated that good flow properties 
as were observed from the various characteristics evaluation 
parameters. The values for angle of repose lied between 26.78°±0.64 
and 34.57°±0.36, Carr’s compressibility index for various formulations 
was in range 12.03–23.08% while the data obtained for Hausner 
ratio ranged between 1.14 and 1.30. The optimized formulation 
OLPM was selected for further experimental evaluation. The 
characteristic FTIR peaks of the drug were obtained at wave numbers 
3197.48 cm−1 (O-H stretching), 763.61 cm−1 (C-Cl stretching), 1459.60 cm−1 
(C=C stretching), 1577.61 cm−1 (C=N stretching), and 2956.14 cm−1 
(C-H stretching). FTIR studies of optimized formulation showed that 
the drug was encapsulated in the microparticles. The spectrum of drug 
sample and microspheres has been shown in Fig. 4. SEM study revealed 
that the discrete, uniformly shaped spherical microspheres were 
obtained (Fig. 5). The DSC trace of LP showed a sharp thermographic 
peak at 279.8 and a broad endothermic peak at the same temperature 
as shown in Fig. 6.
In vitro drug release study for optimized formulation was carried out 
in phosphate buffer pH 6.8 so as to mimic the physiological pH. The 
Table 2: Model summary statistics for dependent variables
Model SD R-squared Adjusted R-squared Predicted R-squared PRESS Significance
Response Mean particle size (Y1), µm
Linear 6.81 0.9142 0.8971 0.8600 757.24
2FI 6.94 0.9200 0.8933 0.7987 1088.84
Quadratic 1.15 0.9983 0.9970 0.9895 56.78 Suggested
Cubic 1.35 0.9983 0.9959 0.9116 478.25
Response Entrapment efficiency (Y2), %
Linear 4.36 0.1455 −0.0254 −0.3903 309.23
2FI 4.59 0.1488 −0.1350 −1.1398 475.93
Quadratic 1.03 0.9665 0.9426 0.8415 35.26 Suggested
Cubic 1.17 0.9694 0.9265 −0.0673 237.39
Response Percent yield (Y3), %
Linear 5.54 0.1181 −0.0583 −0.4678 509.90
2FI 5.82 0.1209 −0.1721 −1.1203 736.55
Quadratic 1.20 0.9711 0.9504 0.8594 48.84 Suggested
Cubic 1.15 0.9810 0.9544 0.5174 167.66 Aliased
Response Drug release at 8th h (Y4), %
Linear 2.02 0.8776 0.8532 0.7831 72.32
2FI 2.12 0.8785 0.8381 0.7452 84.93
Quadratic 1.15 0.9721 0.9522 0.8353 54.90 Suggested
Cubic 0.91 0.9877 0.9705 0.5911 136.33 Aliased
SD: Standard deviation
Table 3: Equations for quadratic model 
Response Intercept A B AB A^2 B^2
Mean particle size (Y1) 120.362 22.0931 −11.4024 −2.7825 6.48837 5.14337
p value < 0.0001 < 0.0001 0.0019 < 0.0001 < 0.0001
Entrapment efficiency (Y2) 79.378 1.74366 1.00192 0.43 −4.62087 −2.77337
p value 0.0020 0.0286 0.4318 < 0.0001 0.0002
Percent yield (Y3) 76.63 1.13 1.96 0.50 −6.14 −2.96
p value 0.0322 0.0024 0.4338 <0.0001 0.0003
Drug release at 8th h (Y4) 76.342 −6.04726 −0.0735786 −0.275 −2.056 −0.771
p value < 0.0001 0.8618 0.6478 0.0022 0.1210
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Table 4: ANOVA responses for surface quadratic model
Source Sum of 
squares
Df Mean square F value p-value Prob>F Significance
Response for (Y1) mean particle size
Model 5399.47 5 1079.89 810.11 <0.0001 Significant
A-Drug: polymer ratio 3904.85 1 3904.85 2929.31 <0.0001
B-Stirring speed 1040.11 1 1040.11 780.26 <0.0001
AB 30.97 1 30.97 23.23 0.0019
A2 292.86 1 292.86 219.70 <0.0001
B2 184.03 1 184.03 138.05 <0.0001
Residual 9.33 7 1.33
Lack of fit 7.60 3 2.53 5.87 0.0601 Not significant
Pure error 1.73 4 0.43
Cor total 5408.80 12
Response for (Y2) entrapment efficiency
Model 214.98 5 43.00 40.44 <0.0001 Significant
A-Drug: polymer ratio 24.32 1 24.32 22.88 0.0020
B-Stirring speed 8.03 1 8.03 7.55 0.0286
AB 0.74 1 0.74 0.70 0.4318
A2 148.54 1 148.54 139.71 <0.0001
B2 53.51 1 53.51 50.32 0.0002
Residual 7.44 7 1.06
Lack of fit 4.26 3 1.42 1.78 0.2894 Not significant
Pure error 3.18 4 0.80
Cor total 222.42 12
Response for (Y3) percent yield
Model 337.33 5 67.47 46.97 <0.0001 Significant
A-drug: polymer ratio 10.21 1 10.21 7.11 0.0322
B-stirring speed 30.81 1 30.81 21.45 0.0024
AB 0.99 1 0.99 0.69 0.4338
A2 262.31 1 262.31 182.62 <0.0001
B2 60.98 1 60.98 42.45 0.0003
Residual 10.05 7 1.44
Lack of fit 5.97 3 1.99 1.95 0.2635 Not significant
Pure error 4.08 4 1.02
Cor total 347.38 12
Response for (Y4) drug release at 8th h
Model 324.10 5 64.82 48.80 <0.0001 Significant
A-drug: polymer ratio 292.55 1 292.55 220.24 <0.0001
B-stirring speed 0.043 1 0.043 0.033 0.8618
AB 0.30 1 0.30 0.23 0.6478
A2 29.41 1 29.41 22.14 0.0022
B2 4.14 1 4.14 3.11 0.1210
Residual 9.30 7 1.33
Lack of fit 7.28 3 2.43 4.80 0.0820 Not significant
Pure error 2.02 4 0.51
Cor total 333.39 12
ANOVA: Analysis of variance
Table 5: Validation of model with checkpoint formulations
S. No. Composition Response variables Experimental values Predicted values Residuals
A (w/w) B (rpm)
CPF 1 2.88 1068 Mean particle Size (Y1), µm 113.57±1.43 114.68 -1.11
Entrapment efficiency (Y2), % 77.49±1.02 79.11 -1.38
Percent Yield (Y3), % 75.03±0.93 76.72 -1.69
Drug Rel at 8th h (Y4), % 77.58±1.57 76.91 0.67
CPF 2 3.64 1023 Mean particle Size (Y1), µm 137.46±0.38 135.77 1.69
Entrapment efficiency (Y2), % 76.98±1.24 78.70 1.72
Percent Yield (Y3), % 74.13±0.26 75.04 -0.091
Drug Rel at 8th h (Y4), % 70.27±1.36 71.56 -1.29
CPF 3 3.09 1034 Mean particle Size (Y1), µm 119.30±1.37 120.77 -1.47
Entrapment efficiency (Y2), % 78.35±1.86 79.60 -1.25
Percent Yield (Y3), % 77.30±0.68 76.94 0.36
Drug Rel at 8th h (Y4), % 74.65±2.72 75.68 -1.03
CPF4 2.74 1093 Mean particle size (Y1), µm 113.02±0.86 111.24 1.78
Entrapment efficiency (Y2), % 77.86±1.65 78.44 -0.58
Percent Yield (Y3), % 75.20±1.46 76.14 -0.99
Drug Rel at 8th h (Y4), % 76.97±2.01 77.59 -0.59
±SD. (n=6). SD: Standard deviation
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optimized formulation showed maximum drug release of 78.36±1.05% 
in 8 h. It was observed that as the drug: polymer ratio was increased that 
the drug release was sustained from the formulation. The dissolution 
data so obtained were then fitted to various drug-release kinetic 
models. The release mechanism was assessed by comparing the values 
of the regression coefficient (r2). The value of the regression coefficient 
was found to be higher for Korsmeyer–Peppas and zero-order model, 
i.e. r2=0.976 and 0.980, respectively.
Evaluation of filled coated capsule shells
The coated capsules were found to be of uniform weight and thickness. 
The coating thickness for these ranged between 0.053 and 0.069 ± 
0.001 mm. The in vitro drug release study was carried out in physiological 
buffers to analyze both lag time in drug release and in vitro dissolution 
data. A period of no drug release was observed for 2 h in SGF pH 1.2 
followed by the release of microspheres in the dissolution medium 
phosphate buffer pH 6.8. The dissolution study was carried out for a 
period of 12 h, and prolonged release was observed from microspheres 
after a lag period of 2 h. Comparative drug release profile from coated 
Fig. 2: Desirability plot for optimized formulation
Fig. 3: Two-dimensional contour and three-dimensional response surface plot showing the effect of Independent variables (A and B) on 
response variables (Y1 – Y4)
Fig. 5: Scanning electron microscope analysis of optimized 
microsphere formulation (OLPM) of losartan potassiumFig. 4: Fourier-transform infraredspectra of (a) losartan 
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Fig. 6: Differential scanning calorimetric analysis of losartan 
potassium and optimized microsphere formulation (OLPM)
capsule shell containing OLPM aimed at stimulating chronotherapeutic 
release of the drug; matching the circadian rhythms and marketed 
formulation (Czartan - 25 mg capsule, Macleods Pharmaceuticals Ltd.) 
is shown in Fig. 7.
DISCUSSION
In the present study, the formulation design protocol was executed in 
three steps; first being the formulation optimization of microparticles 
of losartan potassium followed by its filling into the hard gelatin capsule 
shells. The last step consisted of applying a polymeric coating over the 
filled capsule shell to achieve the necessary lag time of around 2 h.
Emulsion solvent evaporation was found reliable for preparation of 
microparticles of losartan potassium. Span 80 was supplemented 
as an emulsifier to prevent coalescence of droplets during solvent 
evaporation. The data generated by statistical experimental design 
clearly signified that the independent variables (A) and (B), their 
interaction term (AB), and the quadratic terms (A2 and B2) showed a 
significant effect on response variables (Y1-Y4); (p<0.0001). Higher 
polymer concentration produced more viscous dispersion, and 
therefore, shearing effect was less at impeded circulation that formed 
larger droplets [23,24]. Mean particle size decreased with increase in 
stirring speed producing uniform spherical microparticles while in case 
of entrapment efficiency (Y2), it was experiential that an increase in 
polymer concentration in a fixed volume of organic solvent resulted 
in augmenting the entrapment efficiency. In the case of percent yield 
(Y3), it was observed that finer particles formed during the preparation 
of microparticles tend to coalesce to give bigger particles with better 
percent yield. The model applied for drug release at 8th h (Y4) showed 
that the drug release retarded from the formulations as diffusional path 
length for drug release increased while with an increase in stirring 
speed the interfacial area per unit volume increased, so, the drug 
release also increased [19,37-40].
The reliability of the optimization model was further assessed by 
CPFs. The reasonably lower values of residual between predicted 
and observed experimental values for all the four response variables 
indicated a pragmatic agreement between the predicted and trial 
values. Hence, the mathematical model was well fitted. Numerical 
optimization technique using the desirability function approaching 
Fig. 7: Comparative drug release profile marketed formulation (Czartan) and coated capsule shell containing OLPM aimed at stimulating 
the chronotherapeutic release of the drug; matching the circadian rhythms. (a) Circadian variation in BP (Dip at night, surge in 
early morinng; Effective BP management demands chronotherapy based drug release system. (b) drug release pattern in-vitro from 
chronotherapy based capsule dosage from ; Designed for matching the circadium rhythms (Lower drug conc. at night and higher drug 
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1 for obtaining optimized formulation indicated desirable range for 
independent variables A and B to get an optimum response. From the 
contour and response surface plots, it was observed that increasing the 
drug: polymer ratio had a positive effect on all the response variables 
while with increase in stirring speed (B), (Y2), and (Y3) increased 
initially followed by decline or constancy state on further rise in both 
the independent parameters while drug release decreased.
FTIR studies of optimized formulation indicated the absence of 
undesirable chemical interaction between the drug and polymer. 
SEM study revealed that the discrete, uniformly shaped spherical 
microspheres were obtained. DSC results indicated that there is no 
change of LP in a pure state, formulation of microspheres. LP existed 
in an amorphous as a molecular dispersion in the polymeric matrix. 
In vitro drug liberation study for optimized formulation proposed a 
sustained release of drug from microparticles indicating the efficient 
applicability of Eudragit RS100 polymer in controlling the drug release 
of hydrophilic drugs.
Eudragit L100 was found to be optimum for delaying drug release. 
The inclusion of PEG 600 and talc further improvised the coating 
capability by enhancing coating adherence, integrity thus, providing 
flexible coating film with uniform thickness and smoothness after 
drying. Dissolution studies suggested that optimized Eudragit coating 
provided protection against emptying of capsule shell contents for a 
period of 2 h after which the coating dissolved exposing the capsule 
shell to a simulated physiological buffer that resulted in bursting of 
capsule shell thus releasing the formulation components followed by 
a sustained release of losartan potassium from Eudragit RS100 coated 
microspheres.
CONCLUSION
The capsule-based system designed for chronotherapeutic management 
of hypertension dealing with early morning pathology influenced by 
circadian rhythm was successfully prepared and optimized through a 
statistical experimental design approach.
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